Literature DB >> 23852686

Population-based assessment of kaposi sarcoma-associated herpesvirus DNA in plasma among Ugandans.

Fatma M Shebl1, Benjamin Emmanuel, Lisa Bunts, Benon Biryahwaho, Christine Kiruthu, Meei-Li Huang, Ruth M Pfeiffer, Corey Casper, Sam M Mbulaiteye.   

Abstract

Risk of Kaposi sarcoma (KS) is linked to detection of Kaposi sarcoma-associated herpesvirus (KSHV) DNA in plasma, but little is known about the prevalence and risk factors for plasma KSHV DNA detection among the general population where KS is endemic. Correlates of KSHV plasma detection were investigated in a population-based sample of adult Ugandans (15-59 years) who participated in an HIV/AIDS serobehavioral survey in 2004/2005. KSHV DNA was measured in plasma of 1,080 KSHV seropositive and 356 KSHV seronegative persons using polymerase chain reaction (PCR). KSHV DNA in plasma was detected in 157 (8.7%) persons; of these 149 (95%) were KSHV seropositive and 8 (5%) were seronegative. Detection of KSHV DNA in plasma was significantly associated with male sex (P < 0.001), older age (P = 0.003), residence in a rural versus urban area (P = 0.002), geographic region (P = 0.02), and being KSHV seropositive (13.8% seropositive vs. 2.3% seronegative, P < 0.001). In a multivariable model, KSHV DNA plasma quantity was significantly higher in men (P = 0.002), inversely associated with age (P = 0.05), and residing in an urban area (P = 0.01). In Uganda, KSHV is detected more frequently in the plasma of adult males and residents of rural regions, potentially explaining the increased risk of KS in these subsets of the Ugandan population.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  *Kaposi sarcoma; Kaposi sarcoma-associated herpesvirus; epidemiology; plasma; uganda

Mesh:

Substances:

Year:  2013        PMID: 23852686      PMCID: PMC3755768          DOI: 10.1002/jmv.23613

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  37 in total

1.  Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8.

Authors:  K Ariyoshi; M Schim van der Loeff; P Cook; D Whitby; T Corrah; S Jaffar; F Cham; S Sabally; D O'Donovan; R A Weiss; T F Schulz; H Whittle
Journal:  J Hum Virol       Date:  1998 Mar-Apr

2.  Kaposi's sarcoma; an overlooked essay of 1882.

Authors:  F RONCHESE
Journal:  AMA Arch Derm       Date:  1958-05

3.  Geographical and racial differences in the frequency of Kaposi's sarcoma as evidence of environmental or genetic causes.

Authors:  A G OETTLE
Journal:  Acta Unio Int Contra Cancrum       Date:  1962

4.  Risk factors for human herpesvirus 8 seropositivity in the AIDS Cancer Cohort Study.

Authors:  Sam M Mbulaiteye; Jonnae O Atkinson; Denise Whitby; David A Wohl; Joel E Gallant; Scott Royal; James J Goedert; Charles S Rabkin
Journal:  J Clin Virol       Date:  2006-01-18       Impact factor: 3.168

5.  Kaposi's sarcoma in homosexual men-a report of eight cases.

Authors:  K B Hymes; T Cheung; J B Greene; N S Prose; A Marcus; H Ballard; D C William; L J Laubenstein
Journal:  Lancet       Date:  1981-09-19       Impact factor: 79.321

6.  A preliminary communication on extensively disseminated Kaposi's sarcoma in young homosexual men.

Authors:  G J Gottlieb; A Ragaz; J V Vogel; A Friedman-Kien; A M Rywlin; E A Weiner; A B Ackerman
Journal:  Am J Dermatopathol       Date:  1981       Impact factor: 1.533

7.  Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men.

Authors:  Corey Casper; Elizabeth Krantz; Stacy Selke; Steven R Kuntz; Jie Wang; Meei-Li Huang; John S Pauk; Lawrence Corey; Anna Wald
Journal:  J Infect Dis       Date:  2006-11-14       Impact factor: 5.226

8.  Mapping and serodiagnostic application of a dominant epitope within the human herpesvirus 8 ORF 65-encoded protein.

Authors:  C P Pau; L L Lam; T J Spira; J B Black; J A Stewart; P E Pellett; R A Respess
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

9.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.

Authors:  Y Chang; E Cesarman; M S Pessin; F Lee; J Culpepper; D M Knowles; P S Moore
Journal:  Science       Date:  1994-12-16       Impact factor: 47.728

10.  Interassay correlation of human herpesvirus 8 serologic tests. HHV-8 Interlaboratory Collaborative Group.

Authors:  C S Rabkin; T F Schulz; D Whitby; E T Lennette; L I Magpantay; L Chatlynne; R J Biggar
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

View more
  11 in total

1.  Risk Factors for Kaposi's Sarcoma-Associated Herpesvirus DNA in Blood and in Saliva in Rural Uganda.

Authors:  Angela Nalwoga; Marjorie Nakibuule; Vickie Marshall; Wendell Miley; Nazzarena Labo; Stephen Cose; Denise Whitby; Robert Newton
Journal:  Clin Infect Dis       Date:  2020-08-14       Impact factor: 9.079

2.  Kaposi Sarcoma-Associated Herpesvirus in a Rural Ugandan Cohort, 1992-2008.

Authors:  Robert Newton; Nazzarena Labo; Katie Wakeham; Wendell Miley; Gershim Asiki; W Thomas Johnston; Denise Whitby
Journal:  J Infect Dis       Date:  2018-01-04       Impact factor: 5.226

Review 3.  Is human herpesvirus 8 infection more common in men than in women? Systematic review and meta-analysis.

Authors:  Lorin Begré; Eliane Rohner; Sam M Mbulaiteye; Matthias Egger; Julia Bohlius
Journal:  Int J Cancer       Date:  2016-04-26       Impact factor: 7.396

4.  Patterns of human herpesvirus-8 oral shedding among diverse cohorts of human herpesvirus-8 seropositive persons.

Authors:  Rachel A Bender Ignacio; Jason D Goldman; Amalia S Magaret; Stacy Selke; Meei-Li Huang; Soren Gantt; Christine Johnston; Warren T Phipps; Joshua T Schiffer; Richard A Zuckerman; R Scott McClelland; Connie Celum; Larry Corey; Anna Wald; Corey Casper
Journal:  Infect Agent Cancer       Date:  2016-02-10       Impact factor: 2.965

5.  Male hormones activate EphA2 to facilitate Kaposi's sarcoma-associated herpesvirus infection: Implications for gender disparity in Kaposi's sarcoma.

Authors:  Xing Wang; Zhe Zou; Zhaohui Deng; Deguang Liang; Xin Zhou; Rui Sun; Ke Lan
Journal:  PLoS Pathog       Date:  2017-09-28       Impact factor: 6.823

Review 6.  Cancer Risk Studies and Priority Areas for Cancer Risk Appraisal in Uganda.

Authors:  Alfred Jatho; Binh Thang Tran; Jansen Marcos Cambia; Miisa Nanyingi; Noleb Mugume Mugisha
Journal:  Ann Glob Health       Date:  2020-07-07       Impact factor: 2.462

7.  Determinants of Gammaherpesvirus Shedding in Saliva Among Ugandan Children and Their Mothers.

Authors:  Robert Newton; Nazzarena Labo; Katie Wakeham; Vickie Marshall; Romin Roshan; Angela Nalwoga; Ismail Sebina; Lawrence Muhangi; Emily L Webb; Wendell Miley; Rosemary Rochford; Alison M Elliott; Denise Whitby
Journal:  J Infect Dis       Date:  2018-08-14       Impact factor: 5.226

Review 8.  Identification of Human Herpesvirus 8 Sequences in Conjunctiva Intraepithelial Neoplasia and Squamous Cell Carcinoma of Ugandan Patients.

Authors:  Noemy Starita; Clorinda Annunziata; Keith M Waddell; Luigi Buonaguro; Franco M Buonaguro; Maria Lina Tornesello
Journal:  Biomed Res Int       Date:  2015-10-05       Impact factor: 3.411

9.  Rapid Multiplexed Immunoassay for Detection of Antibodies to Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Cathy Logan; Kathryn Todorof; Suzanne P Fiorillo; Thomas B Campbell; John H Elder; Margaret Borok; Ivy Gudza; Lovemore Gwanzura; Buxton Ndemera; Michael J Lochhead; Constance A Benson; Robert T Schooley
Journal:  PLoS One       Date:  2016-09-26       Impact factor: 3.240

10.  Distinct genetic architectures and environmental factors associate with host response to the γ2-herpesvirus infections.

Authors:  Robert Newton; Denise Whitby; Inês Barroso; Neneh Sallah; Wendell Miley; Nazzarena Labo; Tommy Carstensen; Segun Fatumo; Deepti Gurdasani; Martin O Pollard; Alexander T Dilthey; Alexander J Mentzer; Vickie Marshall; Elena M Cornejo Castro; Cristina Pomilla; Elizabeth H Young; Gershim Asiki; Martin L Hibberd; Manjinder Sandhu; Paul Kellam
Journal:  Nat Commun       Date:  2020-07-31       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.